Zydus receives final approval from the USFDA for Lurasidone Hydrochloride Tablets

Deepthi | Myequity news | Date : 22-03-2019 14:54:00 IST

Zydus Cadila has received the final approval from the USFDA to market Lurasidone Hydrochloride Tablets  USP (US RLD Latuda Tablets), in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations.


More from Myequity